Filing Flows › 8-K events › Supernus Pharmaceuticals
Supernus Pharmaceuticals: other events
Form 8-K filed Oct 22, 2026 · items 8.01
FDA decisionsSupernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
What the filing says
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO
Read the filing on SEC EDGAR →
What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →
Supernus Pharmaceuticals at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%. The chart follows the revenue to costs, profit and cash.
Supernus Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
Supernus Pharmaceuticals’s other material 8-Ks
- Nov 2, 2026 — Delisting notices
- Nov 2, 2026 — Changes in control Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
- Oct 26, 2026 — Termination of a material definitive agreement
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.